Clinical Trials Brief | May 25, 2026
This week's five signals cover Bristol Myers Squibb positioning Anthropic's Claude as its enterprise-wide intelligence layer across clinical development and regulatory submissions, FDA approving the first TROP2 antibody-drug conjugate for first-line metastatic triple-negative breast cancer, EMA's CHMP recommending the first oral GLP-1 for weight management in Europe, Japan issuing an emergency safety communication after 20 Tavneos-related deaths from liver injury, and two positive Phase 3 trials establishing inhaled treprostinil as a potential new standard of care for idiopathic pulmonary fibrosis.
Bristol Myers Squibb positions Anthropic's Claude as the shared intelligence platform across its entire global operation
What changed
On May 20, 2026, Bristol Myers Squibb announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions. The agreement moves beyond conversational AI tools toward agentic capabilities integrated into the systems that underpin BMS's science and global operations. Specific clinical development applications include intelligent automation of clinical study reports from underlying trial data, patient safety narrative drafting, and regulatory submission support, with the potential to compress the time between data lock and filing. Anthropic's Head of Life Sciences Eric Kauderer-Abrams described the vision as creating 'a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time.'
Why it matters
This is the clearest signal yet that a top-five pharmaceutical company is treating AI not as a departmental tool but as enterprise infrastructure, comparable to ERP or cloud migration in previous decades. The clinical development applications are particularly significant: if AI can reliably compress the time between data lock and regulatory filing, it addresses one of the longest unexplained delays in the drug development timeline. The agreement also signals that pharma's AI strategy is consolidating around a small number of frontier model providers rather than building proprietary systems. BMS is the second major pharma company this month (after AstraZeneca's Owkin deal) to commit to multi-year AI agent infrastructure.
Takeaway
The pharma industry's AI adoption is entering a consolidation phase where companies are choosing their primary AI platform the way they chose their ERP system in the 2000s. The differentiator is no longer whether a company uses AI, but how deeply it is integrated into regulated workflows like clinical study reporting and regulatory submissions.
Sources
This item is grounded in BMS's May 20, 2026 press release on BioSpace announcing the Anthropic strategic agreement.
FDA approves the first TROP2 antibody-drug conjugate for first-line metastatic triple-negative breast cancer
What changed
On May 22, 2026, FDA approved datopotamab deruxtecan-dlnk (Datroway), developed by AstraZeneca and Daiichi Sankyo, for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval was based on the Phase 3 TROPION-Breast02 trial of 644 patients, which showed datopotamab deruxtecan reduced the risk of disease progression or death by 43% versus chemotherapy (HR 0.57; median PFS 10.8 vs 5.6 months; P < .0001) and improved median overall survival by 5 months (23.7 vs 18.7 months; HR 0.79; P = .0290). The confirmed overall response rate was 64% vs 30%. The drug targets TROP2 (trophoblast cell surface antigen 2) and is administered at 6 mg/kg IV every 3 weeks.
Why it matters
Approximately 70% of metastatic TNBC patients are not candidates for immunotherapy, leaving them with only chemotherapy as a first-line option until now. Datroway establishes a new standard of care for this population with meaningful survival gains. The approval also intensifies the competitive landscape in TROP2-targeted ADCs: both Datroway and Trodelvy now have NCCN Category 1 preferred regimen status in first-line TNBC, and Gilead's sacituzumab govitecan is running a head-to-head trial. The FDA granted Priority Review and the drug is being evaluated simultaneously through Project Orbis in Australia, Canada, Singapore, and Switzerland, with separate reviews underway in the EU, China, and Japan.
Takeaway
For 70% of metastatic TNBC patients who cannot receive immunotherapy, the first-line treatment paradigm has shifted from chemotherapy alone to a targeted ADC with demonstrated overall survival benefit. The TROP2 ADC class is now a multi-product, multi-indication category that will define breast cancer treatment evolution over the next several years.
Sources
This item is grounded in FDA approval reporting from ASCO Post, Healio, OncLive, and Fierce Pharma from May 22, 2026.
CHMP recommends the first oral GLP-1 for weight management in Europe, clearing the way for Wegovy tablets
What changed
On May 21, 2026, EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending an extension to Wegovy's marketing authorisation to add a daily oral tablet (semaglutide 25 mg) for weight management. Wegovy tablets can be used with diet and physical activity in adults with obesity (BMI ≥30) or overweight with at least one weight-related comorbidity. This is the first oral GLP-1 receptor agonist for weight management recommended for approval in the EU. In the OASIS 4 trial, oral semaglutide 25 mg achieved 16.6% mean weight loss, comparable to injectable Wegovy 2.4 mg, with one in three patients achieving 20% or greater weight loss. The CHMP also recommended including cardiovascular risk reduction data from the SELECT trial in the label. The recommendation now goes to the European Commission for final marketing authorisation.
Why it matters
The oral formulation addresses a significant access barrier. Injectable GLP-1 therapies have faced supply constraints, cold-chain logistics challenges, and patient reluctance toward self-injection across Europe. An oral alternative that achieves comparable weight loss (16.6% mean reduction) could substantially expand the addressable patient population while reducing supply chain complexity. From a clinical trials perspective, the approval is based on the OASIS programme, which ran four Phase 3 trials enrolling approximately 1,300 adults. The inclusion of SELECT cardiovascular data in the EU label also means the oral tablet carries a cardiovascular risk reduction claim from Day 1, a notable regulatory decision that positions it as a cardiometabolic medicine rather than just a weight-loss drug.
Takeaway
The EU now has a path to the first oral GLP-1 for obesity. Once the European Commission grants final authorisation, the next bottleneck shifts to member-state pricing and reimbursement decisions, which will determine whether European patients can actually access the tablet. The cardiovascular label claim may accelerate reimbursement arguments.
Sources
This item is grounded in EMA's May 22, 2026 news release, the CHMP variation opinion, and Novo Nordisk's announcement via SEC filing.
Japan issues an emergency Blue Letter for Tavneos after 20 deaths from liver injury, completing a global regulatory cascade
What changed
On May 21, 2026, Japan's Ministry of Health, Labour and Welfare ordered Kissei Pharmaceutical to revise the Tavneos (avacopan) package insert and issue a Blue Letter, the highest level of urgent safety communication in Japan's pharmacovigilance system. The action followed 20 patient deaths associated with liver dysfunction after Tavneos use, with 210 total liver injury reports (including suspected cases) across an estimated 12,000-13,000 patients treated in Japan since the drug's 2022 launch. The label now warns that serious liver dysfunction including vanishing bile duct syndrome (VBDS) can occur, and that fatal cases have been reported. On May 15, Kissei had already requested that physicians refrain from initiating new patients, though this restriction was subsequently eased to allow new prescriptions with mandatory liver function monitoring.
Why it matters
This is now a three-jurisdiction regulatory cascade for the same drug within weeks. In the U.S., FDA proposed withdrawing Tavneos over data manipulation and liver injury. In Japan, the MHLW ordered the highest-level safety communication after 20 deaths. The Japanese signal is particularly significant because 66 of the 76 serious liver injury cases FDA identified came from Japan, meaning the two regulatory actions are addressing the same underlying data from different angles. This is what coordinated global pharmacovigilance looks like in practice: independent regulators reaching similar conclusions about the same drug from shared post-marketing evidence.
Takeaway
The Tavneos story has now expanded from a U.S. data integrity case to a global safety event with regulatory action across three major markets. For sponsors, it demonstrates that post-marketing safety signals can escalate to coordinated multi-jurisdictional action faster than ever before.
Sources
This item is grounded in Japan MHLW Blue Letter reporting from May 21, 2026 and related regulatory documents.
Two positive Phase 3 trials establish inhaled treprostinil as a potential new standard of care for idiopathic pulmonary fibrosis
What changed
On May 19, 2026, United Therapeutics announced positive topline results from both TETON-1 and TETON-2, two Phase 3 trials evaluating inhaled treprostinil (Tyvaso) in idiopathic pulmonary fibrosis. Both trials met their primary endpoint of reduction in disease progression. Tyvaso is already approved for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. If approved for IPF, it would be the first new mechanism approved for the disease since pirfenidone and nintedanib in 2014. United Therapeutics plans to submit a supplemental NDA to FDA.
Why it matters
IPF is a progressive, fatal lung disease with limited treatment options. The antifibrotic drugs approved in 2014 slow progression but do not stop it, and no new mechanism has been approved since. Two positive Phase 3 trials in the same program provides the strongest possible evidence base for regulatory review. The inhaled delivery route and existing approval for related pulmonary conditions means the safety profile is already well-characterized, reducing regulatory uncertainty.
Takeaway
The IPF treatment landscape may be about to change for the first time in nearly a decade. Two positive pivotal trials position inhaled treprostinil as a potential new standard of care, with regulatory submission expected in the near term.
Sources
This item is grounded in United Therapeutics' May 19, 2026 announcement of positive TETON-1 and TETON-2 results.